T. Rowe Price Investment Management, Inc. - DENALI THERAPEUTICS INC ownership

DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 199 filers reported holding DENALI THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.23 and the average weighting 0.3%.

Quarter-by-quarter ownership
T. Rowe Price Investment Management, Inc. ownership history of DENALI THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$13,348
-30.1%
647,0130.0%0.01%
-30.8%
Q2 2023$19,094
+28.1%
647,0130.0%0.01%
+18.2%
Q1 2023$14,908
-15.4%
647,013
+2.2%
0.01%
-21.4%
Q4 2022$17,614
-99.9%
633,358
+50.0%
0.01%
+40.0%
Q3 2022$12,963,000422,3570.01%
Other shareholders
DENALI THERAPEUTICS INC shareholders Q3 2022
NameSharesValueWeighting ↓
Crestline Management, LP 7,460,732$240,012,00028.78%
Casdin Capital, LLC 1,500,000$48,255,0002.16%
Flagship Pioneering Inc. 2,619,968$84,284,0001.98%
INTERNATIONAL BIOTECHNOLOGY TRUST PLC 38,000$8,192,0001.85%
Yiheng Capital Management, L.P. 1,014,684$32,642,0001.49%
SECTORAL ASSET MANAGEMENT INC 207,100$6,662,0001.18%
Artal Group S.A. 600,000$19,302,0000.81%
GILDER GAGNON HOWE & CO LLC 2,619,217$84,260,0000.78%
Temasek Holdings (Private) Ltd 5,369,487$172,736,3970.73%
BRANDYWINE MANAGERS, LLC 9,601$309,0000.53%
View complete list of DENALI THERAPEUTICS INC shareholders